Chemotherapy‐induced peripheral neuropathy in African American cancer survivors: Risk factors and quality of life outcomes

Abstract Background Epidemiological studies of chemotherapy‐induced peripheral neuropathy (CIPN) have predominantly focused on non‐Hispanic White patients, despite the observation that African Americans are more likely to experience CIPN. To address this health disparities gap, we sought to identify...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Matthew R. Trendowski, Christine M. Lusk, Julie J. Ruterbusch, Randell Seaton, Michael S. Simon, Mark K. Greenwald, Felicity W. K. Harper, Jennifer L. Beebe‐Dimmer, Ann G. Schwartz
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	African Americans chemotherapy‐induced peripheral neuropathy health disparities quality of life risk Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/f7126e1a2b374146bee112253b537bb1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f7126e1a2b374146bee112253b537bb1
record_format	dspace
spelling	oai:doaj.org-article:f7126e1a2b374146bee112253b537bb12021-11-22T09:08:48ZChemotherapy‐induced peripheral neuropathy in African American cancer survivors: Risk factors and quality of life outcomes2045-763410.1002/cam4.4328https://doaj.org/article/f7126e1a2b374146bee112253b537bb12021-11-01T00:00:00Zhttps://doi.org/10.1002/cam4.4328https://doaj.org/toc/2045-7634Abstract Background Epidemiological studies of chemotherapy‐induced peripheral neuropathy (CIPN) have predominantly focused on non‐Hispanic White patients, despite the observation that African Americans are more likely to experience CIPN. To address this health disparities gap, we sought to identify non‐genetic risk factors and comorbidities associated with CIPN in African American cancer survivors using the Detroit Research on Cancer Survivors study. Methods Logistic regression was used to evaluate relationships between presence of self‐reported CIPN and relevant clinical characteristics in 1045 chemotherapy‐treated African American cancer survivors. Linear regression was used to evaluate risk factors for CIPN and quality of life outcomes that reflect physical, social, emotional, and functional domains of health. Results Patients with CIPN were more likely to report hypertension (OR = 1.28, 95% CI: 0.98–1.67, p = 0.07), hypercholesterolemia (OR = 1.32, 95% CI: 1.001–1.73, p = 0.05), history of depression (OR = 1.62, 95% CI: 1.18–2.25, p = 0.003), and diabetes (OR = 1.33, 95% CI: 0.98–1.82, p = 0.06) after adjustment for age at diagnosis, sex, and cancer site. BMI (OR = 1.02 kg/m2, 95% CI: 1.006–1.04 kg/m2, p = 0.008) was also positively associated with CIPN. In addition, CIPN status was significantly associated with quality of life (FACT‐G total: β = −8.60, 95% CI: −10.88, −6.32) p < 0.0001) and mood (PROMIS® Anxiety: β = 4.18, 95% CI: 2.92–5.45, p < 0.0001; PROMIS® Depression: β = 2.69, 95% CI: 1.53–3.84, p < 0.0001) after adjustment for age at diagnosis, sex, cancer site, and comorbidities. Neither alcohol consumption (OR = 0.88, 95% CI: 0.68–1.14, p = 0.32) nor tobacco use (ever smoked: OR = 1.04, 95% CI: 0.80–1.35, p = 0.76; currently smoke: OR = 1.28, 95% CI: 0.90–1.82, p = 0.18) was associated with increased CIPN risk. Conclusion Risk factor profiles in African Americans are not entirely consistent with those previously reported for non‐Hispanic White patients. Neglecting to understand the correlates of common chemotherapy‐induced toxicities for this patient population may further contribute to the health disparities these individuals face in receiving adequate healthcare.Matthew R. TrendowskiChristine M. LuskJulie J. RuterbuschRandell SeatonMichael S. SimonMark K. GreenwaldFelicity W. K. HarperJennifer L. Beebe‐DimmerAnn G. SchwartzWileyarticleAfrican Americanschemotherapy‐induced peripheral neuropathyhealth disparitiesquality of liferiskNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancer Medicine, Vol 10, Iss 22, Pp 8151-8161 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	African Americans chemotherapy‐induced peripheral neuropathy health disparities quality of life risk Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	African Americans chemotherapy‐induced peripheral neuropathy health disparities quality of life risk Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Matthew R. Trendowski Christine M. Lusk Julie J. Ruterbusch Randell Seaton Michael S. Simon Mark K. Greenwald Felicity W. K. Harper Jennifer L. Beebe‐Dimmer Ann G. Schwartz Chemotherapy‐induced peripheral neuropathy in African American cancer survivors: Risk factors and quality of life outcomes
description	Abstract Background Epidemiological studies of chemotherapy‐induced peripheral neuropathy (CIPN) have predominantly focused on non‐Hispanic White patients, despite the observation that African Americans are more likely to experience CIPN. To address this health disparities gap, we sought to identify non‐genetic risk factors and comorbidities associated with CIPN in African American cancer survivors using the Detroit Research on Cancer Survivors study. Methods Logistic regression was used to evaluate relationships between presence of self‐reported CIPN and relevant clinical characteristics in 1045 chemotherapy‐treated African American cancer survivors. Linear regression was used to evaluate risk factors for CIPN and quality of life outcomes that reflect physical, social, emotional, and functional domains of health. Results Patients with CIPN were more likely to report hypertension (OR = 1.28, 95% CI: 0.98–1.67, p = 0.07), hypercholesterolemia (OR = 1.32, 95% CI: 1.001–1.73, p = 0.05), history of depression (OR = 1.62, 95% CI: 1.18–2.25, p = 0.003), and diabetes (OR = 1.33, 95% CI: 0.98–1.82, p = 0.06) after adjustment for age at diagnosis, sex, and cancer site. BMI (OR = 1.02 kg/m2, 95% CI: 1.006–1.04 kg/m2, p = 0.008) was also positively associated with CIPN. In addition, CIPN status was significantly associated with quality of life (FACT‐G total: β = −8.60, 95% CI: −10.88, −6.32) p < 0.0001) and mood (PROMIS® Anxiety: β = 4.18, 95% CI: 2.92–5.45, p < 0.0001; PROMIS® Depression: β = 2.69, 95% CI: 1.53–3.84, p < 0.0001) after adjustment for age at diagnosis, sex, cancer site, and comorbidities. Neither alcohol consumption (OR = 0.88, 95% CI: 0.68–1.14, p = 0.32) nor tobacco use (ever smoked: OR = 1.04, 95% CI: 0.80–1.35, p = 0.76; currently smoke: OR = 1.28, 95% CI: 0.90–1.82, p = 0.18) was associated with increased CIPN risk. Conclusion Risk factor profiles in African Americans are not entirely consistent with those previously reported for non‐Hispanic White patients. Neglecting to understand the correlates of common chemotherapy‐induced toxicities for this patient population may further contribute to the health disparities these individuals face in receiving adequate healthcare.
format	article
author	Matthew R. Trendowski Christine M. Lusk Julie J. Ruterbusch Randell Seaton Michael S. Simon Mark K. Greenwald Felicity W. K. Harper Jennifer L. Beebe‐Dimmer Ann G. Schwartz
author_facet	Matthew R. Trendowski Christine M. Lusk Julie J. Ruterbusch Randell Seaton Michael S. Simon Mark K. Greenwald Felicity W. K. Harper Jennifer L. Beebe‐Dimmer Ann G. Schwartz
author_sort	Matthew R. Trendowski
title	Chemotherapy‐induced peripheral neuropathy in African American cancer survivors: Risk factors and quality of life outcomes
title_short	Chemotherapy‐induced peripheral neuropathy in African American cancer survivors: Risk factors and quality of life outcomes
title_full	Chemotherapy‐induced peripheral neuropathy in African American cancer survivors: Risk factors and quality of life outcomes
title_fullStr	Chemotherapy‐induced peripheral neuropathy in African American cancer survivors: Risk factors and quality of life outcomes
title_full_unstemmed	Chemotherapy‐induced peripheral neuropathy in African American cancer survivors: Risk factors and quality of life outcomes
title_sort	chemotherapy‐induced peripheral neuropathy in african american cancer survivors: risk factors and quality of life outcomes
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/f7126e1a2b374146bee112253b537bb1
work_keys_str_mv	AT matthewrtrendowski chemotherapyinducedperipheralneuropathyinafricanamericancancersurvivorsriskfactorsandqualityoflifeoutcomes AT christinemlusk chemotherapyinducedperipheralneuropathyinafricanamericancancersurvivorsriskfactorsandqualityoflifeoutcomes AT juliejruterbusch chemotherapyinducedperipheralneuropathyinafricanamericancancersurvivorsriskfactorsandqualityoflifeoutcomes AT randellseaton chemotherapyinducedperipheralneuropathyinafricanamericancancersurvivorsriskfactorsandqualityoflifeoutcomes AT michaelssimon chemotherapyinducedperipheralneuropathyinafricanamericancancersurvivorsriskfactorsandqualityoflifeoutcomes AT markkgreenwald chemotherapyinducedperipheralneuropathyinafricanamericancancersurvivorsriskfactorsandqualityoflifeoutcomes AT felicitywkharper chemotherapyinducedperipheralneuropathyinafricanamericancancersurvivorsriskfactorsandqualityoflifeoutcomes AT jenniferlbeebedimmer chemotherapyinducedperipheralneuropathyinafricanamericancancersurvivorsriskfactorsandqualityoflifeoutcomes AT anngschwartz chemotherapyinducedperipheralneuropathyinafricanamericancancersurvivorsriskfactorsandqualityoflifeoutcomes
_version_	1718417832435253248

Chemotherapy‐induced peripheral neuropathy in African American cancer survivors: Risk factors and quality of life outcomes

Ejemplares similares